問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Rheumatology

Division of Radiology

Division of General Internal Medicine

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

China Medical University Hospital
Taipei Veterans General Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

李劭軒Li, Shau-Hsuan
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years 1 個月

  • lee056058@gmail.com

  • nana.fen.tw@gmail.com

Recruiting Trial

125Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李劭軒

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Division of Thoracic Medicine

List

9Cases

2022-05-01 - 2026-03-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-11-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2021-06-30 - 2023-11-14

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2023-03-27 - 2029-07-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2019-04-01 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2017-02-10 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Recruiting13Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張家崙
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Hematology & Oncology

2020-04-01 - 2025-11-26

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting4Sites

Terminated1Sites

2015-07-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-08-24 - 2019-09-30

Phase III

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

  • Condition/Disease

    Small-Cell Lung Cancer (SCLC)

  • Test Drug

    Durvalumab; Tremelimumab

Participate Sites
11Sites

Terminated10Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏德椿
China Medical University Hospital-Taipei

未分科

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB